Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy
about
Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancerPutative biomarkers and targets of estrogen receptor negative human breast cancerResistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategiesThe role of HER2 in cancer therapy and targeted drug deliveryA phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer.Targeted Therapy in Breast Cancer.Adaptive changes result in activation of alternate signaling pathways and acquisition of resistance to aromatase inhibitorsHER2: biology, detection, and clinical implicationsHeadway in resistance to endocrine therapy in breast cancer.Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumor.Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.Femara and the future: tailoring treatment and combination therapies with Femara.Does lapatinib work against HER2-negative breast cancers?BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinibPotential use of humanized antibodies in the treatment of breast cancer.Mechanisms of endocrine resistance in breast cancer.Integration of endocrine therapy with targeted agents.Tamoxifen resistance in breast cancer.Resveratrol fuels HER2 and ERα-positive breast cancer behaving as proteasome inhibitor.Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications.Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic.Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells.Correction: Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy.Mechanisms for estrogen receptor expression in human cancerClinical benefit of fulvestrant monotherapy in the multimodal treatment of hormone receptor and HER2 positive advanced breast cancer: a case series
P2860
Q26862550-D75A57B7-C51E-424D-9CA6-81BF3A25EE96Q27003285-7571FE17-D264-40EF-A68B-B54789A1806DQ28072897-B6697D45-6F67-457A-AA29-868391414F51Q34054213-7DD06C02-6853-4276-828C-BD01B2D6838DQ34077853-190F2136-F841-4CE5-A71F-173FD3113359Q34096056-4A03A1C0-7258-4963-BB28-376715F146C9Q35091502-6A0734BE-84C2-4599-AC6E-EA302EA69427Q35622862-D9EC0792-E868-4E65-9E81-69D0B9E4EE8BQ35667708-D834D869-2E91-4E8F-A3B0-476BF7130043Q35776216-805FB1B7-D05F-4B33-967A-EA18F750737EQ35861503-2C000843-5DB4-4555-BBBF-78F9CD2646D1Q35889621-14594292-1AAC-4A4C-A0F7-D7C1B88BFA0BQ36026429-743FA98F-BE42-4389-BEE2-5EA51A05FBDDQ36253050-6EB9DA38-F8A7-4549-813B-85675C64C440Q36299102-91C10280-AE9B-4DA4-9781-BB957E2F20AFQ36532110-57309D96-4767-4A4A-9651-607E3B53D5AAQ36851417-BD70FCA9-F9E5-4106-8490-61DBBCDA7176Q37039801-1102D6E9-252F-49D8-9164-A0DD6F40909EQ37224555-E229D96A-7A81-4619-916C-2CDF58440851Q37715501-82EEE63F-3820-4BF6-BFA2-F4F58858EB35Q38125970-FE25CD96-152B-4EAF-B6D9-FC9E6C39B418Q38214802-D93A73E5-7709-4FA0-9895-B757151DBCA2Q42563273-B3D706E7-2250-4F81-8520-E3616D1B2AE1Q45811718-ECFDB4C0-1019-4E0F-B98D-102F18959C1BQ58718563-47ABA537-F9F8-4A36-A1A2-B80B3EAED3B4Q58764956-062CDCE8-037F-4C8D-9326-240323D21AF4
P2860
Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Reverting estrogen-receptor-ne ...... trastuzumab plus chemotherapy
@ast
Reverting estrogen-receptor-ne ...... trastuzumab plus chemotherapy
@en
Reverting estrogen-receptor-ne ...... trastuzumab plus chemotherapy
@nl
type
label
Reverting estrogen-receptor-ne ...... trastuzumab plus chemotherapy
@ast
Reverting estrogen-receptor-ne ...... trastuzumab plus chemotherapy
@en
Reverting estrogen-receptor-ne ...... trastuzumab plus chemotherapy
@nl
prefLabel
Reverting estrogen-receptor-ne ...... trastuzumab plus chemotherapy
@ast
Reverting estrogen-receptor-ne ...... trastuzumab plus chemotherapy
@en
Reverting estrogen-receptor-ne ...... trastuzumab plus chemotherapy
@nl
P2093
P2860
P356
P1476
Reverting estrogen-receptor-ne ...... trastuzumab plus chemotherapy
@en
P2093
Andrea Rocca
Aron Goldhirsch
Elisabetta Munzone
Franco Nolè
Giuseppe Curigliano
Giuseppe Renne
Giuseppina Bonizzi
P2860
P2888
P356
10.1186/BCR1366
P577
2005-12-07T00:00:00Z
P5875
P6179
1004685072